Synthesized peptide derived from human IRAK4(p-T345/S346)

This antibody detects endogenous levels of IRAK4 only when phosphorylated at Thr345 or Ser346,and dually phosphorylated at two sites.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):VMtsRI

IRAK4

Interleukin-1 receptor-associated kinase 4

Interleukin-1 receptor-associated kinase 4 ;
IRAK-4 ;
Renal carcinoma antigen NY-REN-64 ;

Cytoplasm .

>>MAPK signaling pathway ;
>>NF-kappa B signaling pathway ;
>>Toll-like receptor signaling pathway ;
>>NOD-like receptor signaling pathway ;
>>Neurotrophin signaling pathway ;
>>Alcoholic liver disease ;
>>Pathogenic Escherichia coli infection ;
>>Salmonella infection ;
>>Pertussis ;
>>Yersinia infection ;
>>Leishmaniasis ;
>>Chagas disease ;
>>Toxoplasmosis ;
>>Tuberculosis ;
>>Hepatitis B ;
>>Measles ;
>>Influenza A ;
>>Herpes simplex virus 1 infection ;
>>Epstein-Barr virus infection ;
>>Human immunodeficiency virus 1 infection ;
>>Coronavirus disease - COVID-19 ;
>>Lipid and atherosclerosis